Why Shiseido (4911) Never Worked as a Turnaround Stock
Shiseido's stock may have crossed its 200-day MAV, but it lacks the criteria for a successful turnaround and may still be overpriced.
1k Views
Giant Biogene IPO: Valuation Insights
The China A Share peers have derated due to the sharp sell-off in the last few days. Nevertheless, Biogene is attractively valued at the IPO price...
392 Views
Giant Biogene IPO: Valuation First Look
Giant Biogene will launch its US$500 million HKEx IPO this week. In this note, we present our forecasts and take the first look at its potential...
489 Views
Nikkei 225 Deletions/Additions in March(?) 2022 Due to TSE Market Structure Changes
There is likely to be one Nikkei 225 Change around the end of Q1 2022. There may be more. We will know more on 11 Jan 2022 how many deletions are...
781 Views
Blue Moon Group IPO Trading - Too Expensive for Our Liking but Retail Traders Seem to Like It
Blue Moon Group Holdings (BMG HK) (BMG) raised around US$1.4bn in its Hong Kong listing. The company is backed by Hillhouse who first invested in...
570 Views